GlassScriptPhysician profile
Rolando Gutierrez
NPI 1104841212
$3,604.05
in general payments reported to CMS, 2019-2025
34 companies · $851 in 2025
The $851 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $188 · 2021: $501 · 2022: $582 · 2023: $544 · 2024: $753 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,147.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $458.24 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $434.43 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $314.60 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.52 | 2019-2025 | Jardiance, Tradjenta |
| Amgen INC. | $199.47 | 2021-2024 | Repatha, Otezla |
| Lilly USA, LLC | $174.08 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $170.23 | 2019-2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $144.66 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $143.87 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $112.33 | 2020-2023 | Steglatro, Belsomra |
| Antares Pharma, INC. | $111.18 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Pfizer INC. | $110.33 | 2022-2025 | |
| Galderma Laboratories, L.P. | $110.23 | 2025 | Nemluvio |
| Xeris Pharmaceuticals, INC. | $106.94 | 2023-2025 | Gvoke Hypopen |
| Abbott Laboratories | $105.36 | 2019-2025 | Freestyle Libre 3 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $89.53 | 2020-2021 | |
| Dexcom, INC. | $66.80 | 2019-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $49.06 | 2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $48.23 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $46.63 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $44.72 | 2020-2021 | |
| Verity Pharmaceuticals INC. | $41.70 | 2024-2025 | Tlando |
| Exact Sciences Corporation | $36.18 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $32.87 | 2024-2025 | |
| Allergan, INC. | $31.35 | 2020 | |
| Astellas Pharma US INC | $26.30 | 2024 | Veozah |
| Halozyme INC | $23.34 | 2023 | |
| Mannkind Corporation | $19.72 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.71 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $17.20 | 2023 | Livalo, Seglentis |
| Currax Pharmaceuticals LLC | $15.99 | 2025 | Contrave |
| Circassia INC. | $14.68 | 2019 | |
| Esperion Therapeutics, INC. | $11.63 | 2021 | |
| Amarin Pharma, INC. | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rolando Gutierrez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.